Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80.